drugset / Trial / NCT01562301
Sublingual Anvirzel in Advance Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Withdrawn
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collabNerium Biotechnology · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of Anvirzel (Nerium Oleander) that can be given to lung cancer patients receiving standard therapy with carboplatin and docetaxel. Researchers also want to learn what effect Nerium Oleander may have in combination with carboplatin and docetaxel.
Timeline
- Start
- 2014-06
- Primary completion
- 2016-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OLEANDRIN | Small molecule | 2 mg/m2 | Other |
| Subject | OLEANDRIN | Small molecule | 4 mg/m2 | Other |
| Subject | OLEANDRIN | Small molecule | 8 mg/m2 | Other |
| Subject | OLEANDRIN | Small molecule | 12 mg/m2 | Other |
| Subject | OLEANDRIN | Small molecule | 16 mg/m2 | Other |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |